Tomorrow, for the first time in Medicare's 60-year history, the program will help pay for a medication prescribed solely for weight loss. The Medicare GLP-1 Bridge launches July 1, 2026, giving eligible beneficiaries access to Wegovy, Zepbound, and a brand-new weight-loss pill called Foundayo for a flat $50 monthly copay. CMS estimates millions of Medicare beneficiaries could ultimately access the drugs through this program, out of an estimated 15 to 20 million older adults who may medically qualify. The rules have been finalized only in the past few weeks, and several details surprised even people who'd been following the story closely. If you or someone you care for has been waiting for this, here's exactly what's confirmed, what's still uncertain, and what to do starting tomorrow.
📋Quick Summary
- The Medicare GLP-1 Bridge officially launches July 1, 2026, and runs through December 31, 2027.
- Three medications are covered for weight loss: Wegovy (injection and new pill form), Zepbound KwikPen, and Foundayo, a new oral weight-loss pill.
- Eligibility is based on three BMI-based clinical tiers — not everyone who wants the drugs will qualify.
- The flat $50 monthly copay does NOT count toward your Part D deductible or the $2,100 annual out-of-pocket cap.
- Humana has been selected as the single national processor handling prior authorization and claims for all beneficiaries, regardless of their actual plan.
- The longer-term BALANCE Model, which was supposed to follow the Bridge in 2027, has been shelved indefinitely — leaving no confirmed path forward after December 2027.
- KFF estimates roughly 3.8 million beneficiaries will meet the eligibility requirements at launch.
What's Confirmed as of Launch
When we first covered the GLP-1 Bridge in May, many implementation details were still being finalized. In the weeks since, CMS has released the specifics — and some of them matter a great deal for whether you'll actually be able to use this benefit.
The covered medications list is now final and includes a new addition. Approved for weight loss under the Bridge are Novo Nordisk's Wegovy, available in both injection and tablet form, Eli Lilly's Zepbound KwikPen injection, and a brand-new oral medication called Foundayo, also made by Eli Lilly. Foundayo is notable because it's a daily pill rather than a weekly injection — a meaningful difference for beneficiaries who are uncomfortable with self-injection or have mobility or dexterity limitations that make injections difficult. Ozempic and Mounjaro remain excluded from the weight-loss program because they're FDA-approved for diabetes, not obesity; beneficiaries already using those drugs for diabetes continue through their regular Part D coverage, unaffected by the Bridge.
The eligibility criteria are now precise rather than general. To qualify, a beneficiary must meet one of three clinical tiers: a body mass index of 35 or higher with no additional requirement; a BMI of 30 or higher combined with heart failure, uncontrolled hypertension, or chronic kidney disease; or a BMI of 27 or higher combined with prediabetes, a prior heart attack, a prior stroke, or peripheral artery disease. These tiers are more specific than the general "obesity or related condition" framing used in earlier coverage, and they will exclude some beneficiaries who assumed they'd automatically qualify simply because they wanted to lose weight.
Administratively, CMS has centralized the entire program through a single processor: Humana. Regardless of which Part D plan or Medicare Advantage plan you're actually enrolled in, all Bridge prior authorization requests, claims, and pharmacy payments run through Humana as the designated national processor. This is unusual — Medicare typically lets each plan manage its own claims — but CMS structured the Bridge this way specifically so plans wouldn't need to opt in individually for their members to access it. For the original framing of how this coverage came together, see our earlier piece on whether your 2026 Medicare will actually cover Ozempic or Wegovy.
⚠ Your $50 copay does NOT count toward your drug spending cap.
This detail surprised many policy analysts when it was confirmed: the $50 monthly copay for GLP-1 Bridge medications does not apply toward your Medicare Part D deductible, and it does not count toward the $2,100 annual out-of-pocket cap on prescription drug costs. The Bridge operates as a completely separate payment system from your regular Part D coverage. In practical terms, that means $50 a month — $600 a year — is money spent entirely outside the protections that cap your other drug costs. For a beneficiary already near their $2,100 cap from other medications, the GLP-1 copay is an additional, uncapped expense layered on top. Roughly a quarter of Medicare beneficiaries had an income below $24,600 in 2024, according to KFF — for many in that group, an extra $50 a month, indefinitely, is a real budgeting decision, not a rounding error.
The Uncertainty Nobody Can Resolve Yet
The single most important thing to understand about the GLP-1 Bridge is that it was never designed to be permanent — and the path that was supposed to make it permanent no longer exists.
When CMS first announced the Bridge, the plan was straightforward: an 18-month demonstration program would run from July 2026 through the end of that year, followed immediately by a longer-term framework called the BALANCE Model beginning in January 2027. BALANCE was designed to let Part D plans formally opt into GLP-1 coverage for weight loss as an ongoing benefit, integrated with broader lifestyle and nutrition support. That two-step structure was the basis for earlier reporting, including our own coverage in May, that described the Bridge as a temporary stepping stone to something more lasting.
In April 2026, CMS quietly delayed the Part D portion of the BALANCE Model indefinitely. Instead of moving forward as scheduled, the agency extended the Bridge program itself through December 31, 2027 — buying more time, but without confirming what happens after that date. As Juliette Cubanski, KFF's vice president and director of Medicare policy, put it: "In the short term, we have this temporary program, and then no clear path forward yet as to what will happen at the end of 2027."
This matters enormously for anyone starting GLP-1 treatment now. Physicians who treat obesity have described a specific and difficult concern: starting a patient on a medication that controls a chronic condition, with no guarantee the coverage continues past 18 months, creates a real risk of treatment disruption. Dr. Fatima Cody Stanford, an obesity medicine specialist, noted that this kind of temporary, uncertain coverage "would not happen for diseases other than obesity" — pointing to how differently Medicare treats chronic conditions when the treatment isn't a weight-loss drug.
For beneficiaries, the practical question is whether to start GLP-1 treatment under the Bridge knowing the long-term coverage picture is unresolved, or to wait and see what develops. There's no universally right answer — it depends on your specific health situation and how your doctor weighs the clinical urgency of treatment against the coverage uncertainty.
Related Medicare Updates
✅What This Means for You
Explore Further
How the Process Actually Works Starting Tomorrow
Understanding the mechanics of how to access the Bridge program will save you time and frustration once it launches.
The process starts with your doctor, not with you contacting Medicare directly. Your provider must first send a prescription for an eligible GLP-1 medication to your pharmacy. That action triggers a prior authorization request, which your provider completes and submits through the centralized Bridge system, now confirmed to be processed by Humana regardless of your actual plan. The prior authorization documentation must include your diagnosis, the clinical indication for treatment, your BMI, and any relevant comorbidities supporting one of the three eligibility tiers.
One detail worth understanding clearly: physicians have been told that all prior authorizations under the Bridge will be processed retrospectively — meaning after the prescription has already been sent to the pharmacy, not before. This is a different workflow than beneficiaries may be used to with standard Part D prior authorization, where approval typically happens before a prescription is filled. Practically, this means there may be a period of uncertainty between when your prescription is sent and when the prior authorization is finalized, and your pharmacy may not be able to confirm your $50 copay price immediately at the counter on day one.
Pharmacies do not need to individually opt into the Bridge program to participate — the system is designed so any pharmacy can fill an approved prescription. Major chains have already begun preparing; Walgreens, for example, has announced its nearly 8,000 stores nationwide will support patients navigating the new program, with pharmacists trained to help explain eligibility requirements and answer questions about the participating medications.
Given that this is a brand-new federal program launching from scratch, beneficiaries should expect some early friction. CMS has acknowledged the rollout may not be smooth initially, and is continuing to release implementation guidance as the launch date arrives. If your first attempt to access the Bridge hits a snag — a delayed prior authorization, a pharmacy unfamiliar with the process, a billing confusion — that's a known risk of any program launching this quickly, not necessarily a sign that you don't qualify. For broader context on how AI-driven prior auth is reshaping decisions this year, see our reporting on the WISeR AI prior authorization program.
📊Medicare GLP-1 Bridge: Final Launch Details
Should You Start GLP-1 Treatment Through the Bridge?
This is ultimately a medical decision that belongs between you and your doctor, but there are several practical factors worth weighing as the program goes live.
The clinical case for starting now is straightforward for many beneficiaries: GLP-1 medications have demonstrated significant effectiveness for both weight loss and the cardiovascular and metabolic conditions that often accompany obesity. Dr. Holly Lofton, director of the Medical Weight Management Program at NYU Langone, noted that the coverage "is going to improve access to so many Americans who need these medications, and either are going without or using their hard-earned money in retirement to pay for them." For beneficiaries who've wanted to start treatment but couldn't afford the typical $1,000-plus monthly list price, the Bridge represents a genuine and immediate opportunity.
The case for caution centers on the coverage uncertainty after 2027. If you start GLP-1 treatment, lose weight, and improve related health conditions, the medication often needs to be continued indefinitely to maintain those benefits — these are not typically short-course treatments. A beneficiary who begins under the Bridge and experiences real clinical benefit faces a genuine risk of losing affordable access at the end of 2027 if no permanent program replaces it. That's not a reason to avoid treatment, but it is a conversation worth having with your doctor about contingency planning, including what alternatives — manufacturer assistance programs, potential price reductions from manufacturers competing with the $50 benchmark, or future legislative action — might be available if the Bridge isn't extended.
The financial case requires honest budgeting. Sixty dollars a month sounds manageable in isolation, but for beneficiaries already managing tight margins on a fixed income, and given that this cost sits entirely outside your existing Part D protections, it's worth running the actual numbers for your situation before starting. If premiums and copays are already a strain, our guide to Medicare Savings Programs for 2026 walks through programs that can offset other Medicare costs.
Tomorrow, for the first time, this option exists at all. Whether it's the right option for you is a conversation to have this week, not a decision to make at the pharmacy counter. For a free, unbiased counselor in your state, the Medicare resources directory links to every State Health Insurance Assistance Program (SHIP) office.
